MyHealthChecked PLC - Proposed Sale of Concepta Diagnostics Limited
THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Proposed Sale of Concepta Diagnostics Limited
Designation as an AIM Rule 15 cash shell
Board Changes
Related Party Transaction
Publication of Circular and Notice of General Meeting
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, announces that it has agreed the conditional sale of the Group's trading subsidiary Concepta Diagnostics Limited ("Concepta") to Boots UK Limited ("Boots") for a total consideration of
Concepta distributes and commercialises a range of at-home healthcare and wellness tests and has developed an accompanying proprietary digital platform. The Company has worked closely with Boots to develop its wellness portfolio and digital offering since its launch in
The Disposal
The Disposal, which is conditional upon shareholder approval, will be on a cash free, debt free basis for a total cash consideration to be paid on completion of
The Circular will be available online shortly at: https://investors.myhealthchecked.com/investors/shareholder-information.asp
Upon Completion the Company is expected to become an AIM Rule 15 cash shell with (unaudited) cash balances of approximately
The Board will carefully consider the strategic options available in order to maximise Shareholder value. As the Chairman has experience in utilising cash shells to acquire growing businesses, with a demonstrable record of increasing shareholder value, this will include reviewing acquisition opportunities in a variety of sectors as well as considering a return of cash to Shareholders.
Board Changes and Related Party Transaction
If the Resolutions proposed at the General Meeting are passed by Shareholders, and the Disposal completes,
As part of
As
The Independent Directors of the Company (for these purposes being all the directors other than
Recommendation from Directors
As a standalone business, in its current form, the Company is likely to be loss-making for the foreseeable future. As a result, the Board has concluded that the disposal of Concepta for cash is in the best interests of Shareholders and the Company as a whole. The Directors therefore unanimously recommend that you vote in favour of the Resolutions to be proposed at the General Meeting as they intend to do in respect of their own beneficial holdings currently amounting to 1.91% per cent. of the issued share capital of the Company.
Commenting on Outlook
"Although positive long-term growth is a realistic expectation for wellness testing, the value potential can only be realised via distribution through a variety of services; testing embedded as part of a wider healthcare ecosystem; and the evolution of healthcare driven by government policy.
"During this past year, operational costs have not been offset by COVID sales, demand for which has declined significantly, and despite growth in the sales of wellness tests and tight cost controls, the loss for H1 of the current year has been broadly comparable to the prior year.
"We have regularly updated Shareholders throughout the development of a longstanding working relationship with Boots, which has potential to be a significant player in the growth of home testing. As we look to the future, we have identified Boots as the right partner to take forward the MHC portfolio and drive home-testing as part of a wider range of healthcare services. As an organisation with deep retail product knowledge and pharmacy expertise, the board identified from the onset that a partnership with a trusted brand, with digital reach and a bricks and mortar footprint would be essential in leading the way in growing the sector. It is also clear that our digital platform supports long-term growth potential by underpinning the end-to-end customer journey, which firmly places testing as part of a wider service and product offering and builds a longer-term relationship with the end customer.
"This is a very exciting time for consumer healthcare in the
For further information contact:
|
MyHealthChecked PLC |
|||
|
Penny McCormick, Chief Executive Officer |
via Walbrook PR |
||
|
|
|
||
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
||
|
|
|
||
|
|
|
||
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
||
|
|
|
||
|
|
|
||
|
Walbrook PR Ltd (Media & IR) |
Tel: +44 (0)20 7933 8780 or myhealthchecked@walbrookpr.com |
||
|
|
Mob: +44 (0)7980 541 893 / +44(0)7407 804 654 |
||
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by
The following information has been extracted from the Circular
DISPOSAL OF CONCEPTA DIAGNOSTICS LIMITED
AND
NOTICE OF GENERAL MEETING
Introduction
This Circular sets out details of the proposed disposal by the Company's wholly-owned subsidiary company, Fortis Cardiff Limited, of its wholly-owned subsidiary, Concepta Diagnostics Limited (the "Disposal"), following completion of which, the Company will become an AIM Rule 15 cash shell.
The purpose of this Circular is to provide you with the background to the Disposal, and to explain why the Directors consider the Disposal to be in the best interests of the Company and its Shareholders as a whole and why they recommend that Shareholders should vote in favour of the Resolution to be proposed at the General Meeting.
Shareholders are strongly recommended to read this Circular.
A notice convening a General Meeting to be held in the
Background to and reasons for the Disposal
The principal activity of Concepta, is the distribution and commercialisation of a range of at-home healthcare and wellness tests, and the development of an accompanying proprietary digital platform. The business was previously carried out by Concepta's parent company, Fortis, but was acquired by Concepta when the relevant trade and assets of Fortis were transferred to it under a hive-down arrangement, in exchange for the issue of shares, in
Following the commercialisation of an initial range of COVID testing services, post-pandemic a range of at-home wellness tests were launched to retail by the Group in
As previously reported, we have worked closely with the Buyer to develop the wellness portfolio and digital offering since its launch in
Details of the Disposal
The Company and the Seller have entered into a conditional agreement with the Buyer (the "Disposal Agreement") pursuant to which the Seller has agreed to dispose of Concepta for a consideration of
The Disposal Agreement contains certain customary warranties (including tax warranties) in favour of the Buyer, and the Seller has also agreed to indemnify the Buyer in respect of certain liabilities. The Company has agreed to guarantee the Seller's liabilities under the Disposal Agreement subject to the same limitations of liability applicable to the Seller. The maximum liability of the Seller for all warranty claims under the Disposal Agreement (other than claims for certain fundamental warranties) shall not exceed the consideration payable to it under the Disposal Agreement. The Buyer has obtained a buy-side warranty and indemnity insurance policy which, subject to certain exceptions, provides cover for claims against the Seller and/or the Company up to
The Disposal Agreement is conditional upon, amongst things, the Resolution being passed at the General Meeting and there being no fact, matter, event or circumstance, condition or change arising, occurring or being discovered which amounts to a material adverse change or has a material adverse effect. If the conditions are not satisfied, the Disposal Agreement will terminate. The Company and the Seller are also subject to certain restrictive covenants which, for a period of three years from completion of the Disposal, prevent either of them from, amongst other things, competing with the business of Concepta, soliciting or having business dealings with certain clients or customers of Concepta, and soliciting key employees of Concepta.
The Disposal will represent a fundamental change of business for the Company. This is because, should the Disposal proceed, the Company will become an AIM Rule 15 cash shell.
Change of Name
A term of the Disposal Agreement is that the Company must change its name as soon as reasonably practicable, and in any event within 2 Business Days of completion of the Disposal, to a name that does not use the words "myhealthchecked", as the associated intellectual property rights belong to Concepta.
At a meeting of the Board, and in accordance with the powers granted to the Board pursuant to article 4 of the Company's articles of association, the Directors resolved to change the name of the Company subject to and with effect from completion of the Disposal. A further announcement will be made in due course informing Shareholders of the new name and the effective date of the change.
Financial Information on Concepta Diagnostics Limited
As Concepta only acquired the trade and assets being disposed of from its parent company, Fortis, on
As at
Board Changes
If the Resolution proposed at the General Meeting is passed by Shareholders, and the Disposal completes,
Employee Options and Settlement Terms
The Company has agreed with
In addition, contingent on the disposal of Concepta, the Company intends to pay an exit bonus to
a) Exit bonus: An exit bonus of
b) Share Options: On
As a "Good Leaver" any unexercised unapproved options would normally lapse six months after
In accordance with the terms of the Scheme Rules, five other employees of Concepta will also be determined to hold "Good Leaver" status and as such will be entitled to exercise their options over, in aggregate, 99,999 Ordinary Shares, during an exercise period of 180 days commencing on the date of completion of the Disposal, at an exercise price of
AIM Rule 13 and Related Party Transaction
As
The Independent Directors of the Company (for these purposes being all of the directors other than
Use of Proceeds
On completion of the Disposal the Company is expected to have (unaudited) cash balances of approximately
If the Company becomes an AIM Rule 15 cash shell the Board will carefully consider the strategic options available to it in order to maximise Shareholder value. As the Chairman has experience in utilising cash shells to acquire growing businesses, with a demonstrable record of increasing shareholder value, this will include reviewing acquisition opportunities in a variety of sectors as well as considering a return of cash to Shareholders.
AIM Rule 15
In accordance with AIM Rule 15, the Disposal will constitute a fundamental change of business of the Company. On completion of the Disposal of Concepta, the Company will cease to own or control any of its existing activities or assets.
The Company will therefore become an AIM Rule 15 cash shell and, as such, will be required to make an acquisition or acquisitions which constitutes a reverse takeover under AIM Rule 14 (including seeking re-admission as an investing company (as defined under the AIM Rules) on or before the date falling six months from completion of the Disposal or be re-admitted to trading on AIM as an investing company under the AIM Rules (which requires the raising of at least
AIM Rule Deadlines - Reverse Takeover
Any failure in completing an acquisition or acquisitions which constitute(s) a reverse takeover under AIM Rule 14 (including seeking re-admission as an investing company (as defined under the AIM Rules)) will result in the cancellation of the Company's Ordinary Shares from trading on AIM.
Following the completion of the Disposal, the Company will be dependent upon the ability of the Board to identify suitable acquisition targets. As at the date hereof, the Directors have not identified any opportunities which they have resolved to pursue. There is therefore no guarantee that the Company will be able to acquire an identified opportunity at an appropriate price, or at all, as a consequence of which cash resources and management time might be expended on investigative work and due diligence.
Market conditions may also have a negative impact on the Company's ability to make an acquisition, or acquisitions, which constitute a reverse takeover under AIM Rule 14. There is therefore no guarantee that the Company will be successful in meeting the AIM Rule 15 deadline as described above.
The Company expects to incur certain third-party costs associated with the sourcing of suitable acquisition or acquisitions. The Company can give no assurance as to the level of such costs, and given that there can be no guarantee that negotiations to acquire any given target business will be successful, the greater the number of deals that do not reach completion, the greater the likely impact of such costs on the Company's performance, financial condition and business prospects.
Shareholders' Approval
Set out at the end of this Document is a notice convening the General Meeting to be held on
1. That the Disposal be approved for the purposes of Rule 15 of the AIM Rules.
If the Resolution is not passed, the Disposal will not proceed.
Action to be taken by Shareholders
You will find enclosed with this Document a Form of Proxy for use at the General Meeting. You are requested to complete and return the Form of Proxy to the Registrar, in accordance with the instructions printed thereon as soon as possible but, in any event, to be received no later than
Recommendation
The Directors, believe the Disposal is in the best interests of Shareholders and the Company as a whole and accordingly recommend that the Shareholders vote in favour of the Resolution.
Accordingly, the Directors unanimously recommend that you vote in favour of the Resolution to be proposed at the General Meeting as they intend to do in respect of their own beneficial holdings currently amounting to 1.91% per cent. of the issued share capital of the Company.
The Directors have considered the alternatives to the Disposal and have concluded that proceeding with the Disposal and becoming an AIM Rule 15 cash shell is most likely to represent the best value to the Shareholders in the long term.
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
|
Date of publication of this document |
|
|
Last date and time for receipt of Forms of Proxy |
|
|
General Meeting |
|
|
Announcement of Result of Meeting |
|
|
Completion of the Disposal |
On or before |
If any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of a Regulatory Information Service announcement. All events listed in the above timetable following the General Meeting are conditional on the passing of the resolutions at the General Meeting.
References to time in this document and the Notice of General Meeting are to
DEFINITIONS
The following words and expressions shall have the following meanings in this document unless the context otherwise requires:
|
''AIM'' |
the AIM market operated by the London Stock Exchange
|
|
''AIM Rules'' |
the rules for AIM companies as published by the London Stock Exchange from time to time
|
|
''Board'' or ''Directors'' |
the directors of the Company at the date of this document
|
|
"Buyer" |
Boots UK Limited, a company registered in
|
|
"Business Day" |
a day other than a Saturday, Sunday or public holiday in
|
|
''certificated" or "in certificated form" |
a share or other security which is not in uncertificated form (that is, not in CREST)
|
|
"Circular" |
this circular to shareholders dated
|
|
"Company'' or ''MyHealthChecked" |
MyHealthChecked PLC, a company registered in
|
|
"Concepta" or "CDL"
|
Concepta Diagnostics Limited a company registered in |
|
''CREST'' |
the computerised settlement system to facilitate transfer of title to or interests in securities in uncertificated form operated by Euroclear UK & International Limited
|
|
"Disposal" |
the proposed disposal of Concepta to the Buyer
|
|
"Disposal Agreement" |
the conditional share and purchase agreement dated
|
|
''Form of Proxy'' |
the form of proxy for use at the General Meeting which accompanies this document
|
|
"Fortis" or "Seller"
|
Fortis Cardiff Limited, a company registered in
|
|
''General Meeting'' or "GM" |
the general meeting of the Company, notice of which is set out at the end of this document, and any adjournment thereof
|
|
"Group" |
the Company and its subsidiary undertakings
|
|
"London Stock Exchange''
|
London Stock Exchange plc
|
|
"Neville Registrars'' |
Neville Registrars Limited, the Company's registrars
|
|
''Notice of General Meeting'' |
the notice of the General Meeting, which is set out at the end of this document
|
|
"Ordinary Shares" |
ordinary share of
|
|
''Regulatory Information Service'' |
a service approved by the FCA for the distribution to the public of regulatory announcements and included within the list maintained on the FCA's website |
|
''Resolution'' |
the resolution to be proposed at the General Meeting, as set out in the Notice of General Meeting
|
|
"Scheme Rules" |
the Concepta PLC 2016 EMI Share Option Scheme
|
|
"Shareholder'' |
holder of Ordinary Shares
|
|
''
|
the |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE